HighLife is a Paris-based medical device company developing transcatheter solutions for structural heart disease, centered on a trans-septal transcatheter mitral valve replacement (TMVR) system for patients with moderate-to-severe or severe mitral regurgitation. Its two-component valve-in-ring design, with ring and valve both implanted percutaneously, mirrors the surgical gold standard of annuloplasty ring plus valve. Founded in 2010, the company is headquartered in Paris, operates a US facility in Irvine, California, and received CE Mark approval for both its TMVR system and the next-generation Clarity Valve in 2026.
1
Round
1
Industry
3
Tags
Sep 22, 2026
Latest raise
Funding activity · 1 round
Sep 22, 2026
$90M
Series C+
Led by Supernova Invest
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
